Peplens

Adipotide

Preclinical

Synthetic chimeric proapoptotic peptidomimetic (adipose-vasculature-targeting) · Also known as FTPP, fat-targeted proapoptotic peptide, prohibitin-targeting peptide 1, CKGGRAKDC-GG-D(KLAKLAK)2

Overview

Adipotide is a synthetic chimeric peptide designed to selectively destroy the blood supply of white fat tissue: a homing sequence targets prohibitin/ANXA2 on the vasculature feeding white adipose tissue, linked to a proapoptotic (cell-death-triggering) sequence, so the targeted blood vessels regress and fat cells die. In preclinical studies it produced striking weight loss — roughly 30% in obese mice and about 11% body-weight reduction in obese rhesus monkeys, with improved insulin sensitivity. However, it never demonstrated a viable human profile: an early-phase human (Phase 1) trial was undertaken but development was halted, with nephrotoxicity (kidney injury / renal lesions) a key concern, and clinical development was ultimately discontinued. There is no credible human efficacy or safety evidence supporting use, and any marketing of it for weight loss is unproven and inadvisable.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

  • Fat loss / weight reduction (marketed claim; preclinical only — not validated in humans and development was halted)
  • Metabolic / insulin-sensitivity improvement — preclinical animal observation, not established in humans

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

  • Labs — renal function (creatinine, eGFR, urinalysis): kidney toxicity was the signal that helped end its development — a major safety concern, not a casual metric
  • Body weight — smart-scale trend (contextual only; human efficacy is unproven)
  • Body composition — InBody/DEXA body-fat % (contextual only)
  • Subjective — hydration status, energy, and any signs of dehydration

Sources & References

  1. [1]Prohibitin-targeting peptide 1 (adipotide) — Wikipedia (mechanism, preclinical results, discontinued development)
  2. [2]Reversal of obesity by targeted ablation of adipose tissue (adipotide in primates) — ScienceDaily summary

Quick Reference

Class
Synthetic chimeric proapoptotic peptidomimetic (adipose-vasculature-targeting)
Evidence Level
Preclinical
Reported Uses
2 listed
Tracking Metrics
4 suggested
Citations
2 sources

Safety & legal notes

NOT FDA-approved for any indication. Despite dramatic animal weight-loss results, adipotide did not advance past early human studies — development was discontinued, with nephrotoxicity (kidney injury) a notable safety signal. There is no adequate human efficacy or safety evidence; it is sold, if at all, only as a research chemical and should not be regarded as a usable weight-loss agent. Athletes should verify current rules with their governing body. Consult a licensed clinician.

Track your protocol in Peplens

Connect your InBody, Whoop, smart scale, and nutrition data. See your Overlay — all metrics, one clear read.

Get started free →
← All entries